The European Commission (EC) has approved cabozantinib (Cabometyx) for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (Nexavar), according to Ipsen, which develops the multikinase inhibitor with Exelixis.1
Cabozantinib was initially approved by the FDA as a treatment for patients with medullary thyroid cancer in 2012. In April 2016, the multikinase inhibitor was granted an indication as a treatment for patients with advanced renal cell carcinoma (RCC) following one prior antiangiogenic therapy; it received this indication in the European Union in September 2016. This approval was further expanded in December 2017 to include the treatment of patients with advanced RCC in the frontline setting, followed by the EC to grant the same approval in May 2018.
- European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the treatment of hepatocellular carcinoma in adults previously treated with sorafenib. Ipsen. Published November 15, 2018.Accessed November 15, 2018. https://bit.ly/2PtjvDH.
- Abou-Alfa GK, Meyer T, Cheng A-L, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Eng J Med. 2018;379:54-63. doi: 10.1056/NEJMoa1717002.
... to read the full story